Oncology-Focused Biotech Selects Medidata

Published on: 

Applied Clinical Trials

Start-up biotech selects Medidata Rave for Phase I and II trials of its investigational compound to address solid tumors and blood cancers.

Forty Seven Inc., a Stanford University start-up biotech specializing in cancer immunotherapy, will use Medidata’s electronic data capture, management and reporting system Medidata Rave in two of its upcoming Phase I and Phase II trials. Forty Seven takes its name from CD47 tumor cell protein that its lead molecule, Hu5F9-G4-an experimental monoclonal cancer drug-to be tested in solid tumor and blood cancers.

Read the full release.